ESL1 Antibody

What is ESL-1 and where is it expressed in the cellular context?

ESL-1 (E-selectin ligand-1) is a high-affinity glycoprotein ligand that participates in the binding of myeloid cells to E-selectin. The sequence of mouse ESL-1 shows high homology to the cysteine-rich FGF receptor (CFR) in chicken and the rat Golgi protein MG160. ESL-1 has a unique subcellular distribution pattern, being localized both in the Golgi apparatus and on the cell surface of leukocytes. Notably, immunofluorescence and biochemical analyses have confirmed its dual localization .

Cell surface distribution studies using immunogold scanning electron microscopy have demonstrated that approximately 80% of ESL-1 is concentrated on microvilli of leukocytes, which are sites specifically designed for initiating contact with endothelium. This contrasts with control antigens like B220, which predominantly localize (69%) to the planar cell surface . In the hematopoietic system, ESL-1 is strongly elevated in hematopoietic progenitor cells compared to mature cells, correlating with its prominent function in E-selectin binding and migration of these progenitors to the bone marrow .

How does ESL-1 function in the context of E-selectin binding and cell recruitment?

In the context of hematopoietic stem and progenitor cells (HSPCs), ESL-1 plays a more dominant role in E-selectin binding and migration to the bone marrow. This functional shift from ESL-1 dominance in immature compartments to PSGL-1 dependence in mature neutrophils represents a critical regulatory mechanism in myeloid homeostasis and inflammatory responses .

What methodological approaches can be used to detect ESL-1 expression in different cell types?

Detection of ESL-1 requires a combination of techniques to account for its dual localization in the Golgi and cell surface:

• Flow cytometry: Surface ESL-1 can be detected using specific antibodies against extracellular domains. Cell surface biotinylation followed by flow cytometry has confirmed ESL-1 surface expression, with cells sorted as ESL-1^high and ESL-1^low exhibiting corresponding high and low immunoprecipitation signals .

• Immunofluorescence microscopy: Indirect immunofluorescence with anti-ESL-1 antibodies has been successfully used to visualize both Golgi and cell surface localization. For optimal detection of Golgi-localized ESL-1, cells must be fixed and permeabilized prior to antibody staining .

• Western blotting: For quantitative assessment of ESL-1 expression across different cell types, western blotting can be performed using anti-ESL-1 antibodies. In published protocols, approximately 10^5 myeloid cells or 1.5×10^5 lymphocytes are typically loaded per lane on 7.5% SDS-PAGE gels, followed by transfer to nitrocellulose membranes and detection with anti-ESL-1 rabbit serum (1:1,000 dilution) and HRP-conjugated secondary antibodies .

How can ESL-1 antibodies be used to investigate hematopoietic stem cell dynamics?

ESL-1 antibodies serve as critical tools for investigating hematopoietic stem cell (HSC) dynamics, particularly in relation to cell cycle regulation and bone marrow homing. Research has revealed that ESL-1 controls HSPC cycling and numbers in vivo, with ESL-1-deficient (Glg1^-/-^) mice showing significant alterations in hematopoietic stem and progenitor cell proliferation .

For cell cycle analysis experiments, researchers can employ the following protocol using ESL-1 antibodies in conjunction with proliferation markers:

• Isolate bone marrow cells and enrich for lineage-negative cells using immunomagnetic depletion.

• Stain cells with biotinylated CD48 and streptavidin-Alexa Fluor 405, anti-Sca-1-APC, anti-c-Kit-PE-Cy7, and anti-CD150-PE to identify primitive hematopoietic populations.

• Fix and permeabilize cells using Cytoperm/Cytofix kit (BD Biosciences).

• For BrdU incorporation, incubate with DNase I at 37°C for 1 hour, then stain with anti-BrdU-APC.

• For Ki67 detection, use mouse Foxp3 fixation and permeabilization buffers, followed by anti-Ki67-Alexa600 and Hoechst 33342 nuclear staining.

• Analyze by flow cytometry to determine proliferation status of ESL-1-positive versus ESL-1-negative HSPCs .

This approach has revealed that Glg1^-/-^ mutants display reductions in proliferating Lineage^NEG^cKit^HI^Sca1^+^ (LSK) cells and more primitive LSK CD48^NEG^ and LSK CD48^NEG^CD150^+^ precursors, confirming ESL-1's role in promoting homeostatic proliferation of HSPCs .

What are the optimal conditions for immunoprecipitation studies using ESL-1 antibodies?

Immunoprecipitation (IP) of ESL-1 requires careful optimization due to its dual localization and glycoprotein nature. For surface-specific ESL-1 IP, the following methodological considerations should be addressed:

• Cell surface IP protocol:

  • Perform cell surface biotinylation of intact cells using Sulfo-NHS-LC-Biotin.

  • Lyse cells in buffer containing 1% NP-40, 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), and protease inhibitors.

  • Pre-clear lysates with protein G-Sepharose.

  • Incubate cleared lysates with anti-ESL-1 antibodies (typically 2-5 μg per 10^7 cells).

  • Capture immune complexes with protein G-Sepharose and wash extensively.

  • Elute bound proteins by boiling in Laemmli sample buffer with 50 mM DTT.

  • Analyze by SDS-PAGE and western blotting with streptavidin-HRP to confirm surface origin .

• Total cell ESL-1 IP:

  • For total cellular ESL-1 (including Golgi-resident fraction), cells should be lysed directly without surface biotinylation.

  • Use RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl pH 8.0) with protease inhibitors to ensure solubilization of Golgi membranes.

  • Follow standard IP procedure as above.

  • Detect with anti-ESL-1 primary antibodies (1:1,000 dilution) followed by HRP-conjugated secondary antibodies .

When comparing IP results between different cell populations (e.g., mature leukocytes vs. hematopoietic progenitors), it is essential to normalize loading to account for potential differences in ESL-1 expression levels between cell types.

How can researchers validate the specificity of ESL-1 antibodies in their experimental systems?

Validating antibody specificity is crucial for ensuring reliable research outcomes. For ESL-1 antibodies, the following comprehensive validation strategy is recommended:

• Genetic validation:

  • Compare antibody staining in wild-type versus Glg1^-/-^ (ESL-1-deficient) cells as the gold standard for specificity.

  • If knockout models are unavailable, siRNA or shRNA knockdown of ESL-1 can serve as alternatives.

• Blocking peptide competition:

  • Pre-incubate the ESL-1 antibody with excess purified ESL-1 protein or immunizing peptide.

  • Perform parallel staining with blocked and unblocked antibody.

  • Specific staining should be significantly reduced or eliminated in the blocked sample.

• Multiple antibody concordance:

  • Use at least two antibodies targeting different epitopes of ESL-1.

  • Compare staining patterns across techniques (flow cytometry, immunofluorescence, western blotting).

  • Consistent results across different antibodies increase confidence in specificity.

• Cross-reactivity assessment:

  • Test antibody reactivity against potential cross-reactive proteins, particularly those with sequence homology to ESL-1 (e.g., CFR, MG160).

  • Perform immunoprecipitation followed by mass spectrometry to identify all proteins recognized by the antibody.

This multi-faceted approach ensures that observed signals are truly attributable to ESL-1 and not to non-specific binding or cross-reactivity with related proteins .

What are the key technical considerations for flow cytometric analysis of ESL-1?

Flow cytometric detection of ESL-1 requires careful optimization due to its variable surface expression and potential masking by heavily glycosylated structures. Based on published protocols, the following methodological details should be considered:

• Antibody selection and titration:

  • Use antibodies validated for flow cytometry specifically.

  • Perform detailed titration experiments to determine optimal antibody concentration.

  • For mouse ESL-1, anti-ESL-1 rabbit serum has been successfully used at 1:100-1:200 dilution followed by fluorophore-conjugated secondary antibodies .

• Surface versus intracellular staining:

  • For surface-only ESL-1 detection, stain unfixed cells on ice to prevent internalization.

  • For total ESL-1 detection, fix cells with 2% paraformaldehyde and permeabilize with cold methanol or commercial permeabilization buffers.

  • Compare surface-only versus total staining to assess ESL-1 distribution between surface and Golgi compartments.

• Multiparameter analysis strategy:

  • For hematopoietic progenitor analysis, combine ESL-1 staining with lineage markers, c-Kit, Sca-1, CD48, and CD150 to identify specific progenitor populations.

  • Include viability dye to exclude dead cells, which can bind antibodies non-specifically.

  • Use fluorescence-minus-one (FMO) controls to set accurate gates for ESL-1 positivity .

• Cell sorting considerations:

  • If sorting ESL-1-positive cells for downstream applications, use lower antibody concentrations to minimize potential functional effects.

  • Sort directly into appropriate media containing serum to maintain cell viability.

  • Confirm sorted population purity by post-sort analysis .

How can researchers effectively study the functional relationship between ESL-1 and E-selectin?

Investigating the functional relationship between ESL-1 and E-selectin requires specialized methodologies that assess both binding interactions and downstream biological effects. The following approaches have proven effective:

• E-selectin binding assays:

  • Flow-based adhesion assays: Use parallel plate flow chambers coated with recombinant E-selectin to assess ESL-1-dependent rolling and adhesion under physiological shear stress conditions.

  • Static binding assays: Incubate cells with soluble E-selectin-Fc fusion proteins, followed by fluorescent secondary antibodies and flow cytometric quantification.

  • Competitive inhibition: Pre-incubate cells with blocking antibodies against ESL-1, PSGL-1, or CD44 to determine their relative contributions to E-selectin binding .

• In vivo migration studies:

  • Inject fluorescently labeled hematopoietic progenitor cells from wild-type or Glg1^-/-^ donors into recipient mice.

  • Analyze bone marrow homing efficiency using flow cytometry at defined time points (typically 12-24 hours post-transplantation).

  • For inflammatory models, assess neutrophil recruitment to inflamed tissues in the presence or absence of ESL-1, PSGL-1, or E-selectin blocking antibodies .

• Mechanistic studies:

  • Investigate E-selectin-induced signaling events in the presence or absence of ESL-1 using phospho-specific antibodies against key signaling mediators.

  • Perform pull-down assays with GST-tagged cytoplasmic domain of ESL-1 to identify binding partners involved in signal transduction.

  • Use site-directed mutagenesis of ESL-1 glycosylation sites to identify critical residues for E-selectin recognition .

These approaches have revealed that ESL-1 cooperates with PSGL-1 for E-selectin binding, with ESL-1 dominating in hematopoietic progenitor cells and PSGL-1 playing a more prominent role in mature neutrophils .

What experimental design strategies are effective for studying ESL-1's role in stem cell proliferation?

ESL-1 has been identified as a critical regulator of hematopoietic stem and progenitor cell (HSPC) proliferation. To effectively investigate this function, the following experimental design strategies are recommended:

• In vivo proliferation analysis:

  • Administer BrdU to wild-type and Glg1^-/-^ mice via intraperitoneal injection (typically 1-2 mg per mouse).

  • After 12-24 hours, isolate bone marrow cells and analyze BrdU incorporation in defined HSPC populations by flow cytometry.

  • Complement BrdU incorporation with Ki67/Hoechst staining to determine cell cycle status (G0 vs. G1/S/G2/M).

  • Quantify the frequency of proliferating (BrdU^+^ or Ki67^+^) cells within LSK, LSK CD48^NEG^, and LSK CD48^NEG^CD150^+^ populations .

• Transplantation studies:

  • Perform competitive bone marrow transplantation using wild-type and Glg1^-/-^ donors with distinguishable markers (CD45.1 vs. CD45.2).

  • Assess donor chimerism in peripheral blood and bone marrow at regular intervals (4, 8, 12, and 16 weeks post-transplant).

  • Measure functional HSC frequency using limiting dilution assays.

  • Test resistance to hematopoietic exhaustion by administering 5-fluorouracil at 10-day intervals and monitoring survival .

• In vitro proliferation assays:

  • Isolate LSK cells from wild-type and Glg1^-/-^ mice and culture in the presence of stem cell factor, thrombopoietin, and FLT3 ligand.

  • Track cell divisions using CellTrace Violet or CFSE dilution.

  • Test the effect of TGFβ pathway modulation by adding TGFβ receptor inhibitors or neutralizing antibodies.

  • Analyze cell cycle status at defined time points using propidium iodide staining or Ki67/Hoechst co-staining .

Research using these approaches has demonstrated that ESL-1 deficiency leads to increased quiescence and enhanced survival of HSPCs, with Glg1^-/-^ mice showing dramatic resistance to hematopoietic exhaustion induced by repeated 5-FU administration .

What are common challenges in ESL-1 antibody experiments and how can they be addressed?

Researchers working with ESL-1 antibodies frequently encounter several technical challenges. The following troubleshooting guide addresses these issues with practical solutions:

Implementing these solutions has been shown to significantly improve the reliability and reproducibility of ESL-1 antibody-based experiments across different applications .

How should researchers interpret conflicting data when ESL-1 antibodies show different patterns across techniques?

When ESL-1 antibodies yield apparently conflicting results across different techniques, systematic analysis and interpretation are essential. Consider the following strategy for resolving discrepancies:

• Evaluate technique-specific factors:

  • Flow cytometry may detect only surface ESL-1, while western blotting captures total cellular ESL-1.

  • Immunofluorescence can reveal subcellular localization but may be affected by fixation and permeabilization conditions.

  • Functional assays may be influenced by antibody-mediated perturbation of ESL-1 interactions.

• Consider epitope accessibility:

  • Different antibody clones recognize distinct epitopes that may be differentially masked by glycosylation or protein interactions.

  • Compare results from antibodies targeting different regions of ESL-1 (N-terminal, C-terminal, central domains).

  • Test whether deglycosylation affects antibody recognition patterns.

• Assess biological context:

  • ESL-1 expression and localization vary across cell types and activation states.

  • In hematopoietic progenitors, ESL-1 levels are elevated compared to mature cells.

  • During inflammation, ESL-1 function may be modulated by post-translational modifications.

• Validate with orthogonal approaches:

  • Complement antibody-based detection with mRNA analysis (qPCR, RNA-seq).

  • Use genetic models (Glg1^-/-^ cells or knockdown) to confirm specificity.

  • Employ mass spectrometry-based proteomics to quantify ESL-1 expression and modifications.

Research has shown that ESL-1 has dual localization in the Golgi and on microvilli of the cell surface, which can lead to apparently conflicting results depending on the detection method. The predominant localization may also vary by cell type, with elevated expression in hematopoietic progenitors compared to mature cells .

How can researchers determine if ESL-1 antibodies are affecting cellular function in their experiments?

When using ESL-1 antibodies in functional studies, it is critical to determine whether the antibodies themselves alter cellular behavior. The following methodological approach helps assess potential antibody-mediated effects:

• Concentration-dependent functional assays:

  • Perform dose-response experiments with increasing antibody concentrations.

  • Monitor cellular functions (proliferation, migration, signaling) across the dose range.

  • Establish the minimum effective concentration for detection that does not impact function.

• Control antibody comparisons:

  • Include isotype-matched control antibodies at identical concentrations.

  • Use F(ab) and F(ab')₂ fragments to distinguish Fc-dependent from binding-site-dependent effects.

  • Compare multiple anti-ESL-1 antibody clones targeting different epitopes.

• Time-course analysis:

  • Assess acute versus chronic antibody exposure effects.

  • Monitor cellular responses at multiple time points after antibody addition.

  • Determine if effects are reversible upon antibody removal.

• Genetic validation:

  • Compare antibody effects in wild-type versus Glg1^-/-^ cells.

  • If antibody effects persist in knockout cells, this indicates off-target activity.

  • Use siRNA knockdown as an alternative approach if genetic models are unavailable.

These approaches have revealed that some anti-ESL-1 antibodies can interfere with E-selectin binding and downstream functions, particularly at high concentrations or with extended exposure times. Using F(ab')₂ fragments can minimize these effects while still allowing detection .

How can ESL-1 antibodies be utilized to investigate the TGFβ pathway in hematopoietic stem cells?

Recent research has uncovered a previously unknown relationship between ESL-1 and TGFβ signaling in hematopoietic stem cells. ESL-1 antibodies can be instrumental in exploring this connection through the following approaches:

• Co-localization studies:

  • Perform dual immunofluorescence staining for ESL-1 and TGFβ receptors or downstream signaling molecules.

  • Use confocal microscopy to assess spatial relationships between ESL-1 and TGFβ pathway components.

  • Quantify co-localization using Pearson's correlation coefficient or Manders' overlap coefficient.

• Signaling pathway analysis:

  • Use anti-ESL-1 antibodies to immunoprecipitate ESL-1 complexes and analyze associated proteins.

  • Probe for TGFβ pathway components by western blotting.

  • Compare pSmad2/3 levels between wild-type and Glg1^-/-^ cells by immunofluorescence or flow cytometry.

  • Design co-culture experiments with CXCL12-expressing niche cells to test TGFβ-mediated effects .

• Functional modulation studies:

  • Combine ESL-1 antibody treatment with TGFβ pathway inhibitors in in vitro proliferation assays.

  • Assess whether TGFβ blockade rescues proliferation defects in ESL-1-deficient cells.

  • Monitor changes in cell cycle distribution and quiescence markers in response to combined ESL-1/TGFβ manipulation .

Research using these approaches has demonstrated that ESL-1 deficiency leads to enhanced TGFβ signaling in hematopoietic stem cells, as evidenced by increased nuclear pSmad2/3 levels. Moreover, TGFβ neutralization partially rescues the proliferation defect observed in Glg1^-/-^ LSK cells, suggesting a mechanistic link between ESL-1 and TGFβ pathway regulation .

What advanced imaging techniques can be combined with ESL-1 antibodies for deeper biological insights?

Combining ESL-1 antibodies with cutting-edge imaging technologies enables more sophisticated analyses of ESL-1 biology. The following advanced techniques offer particular promise:

• Super-resolution microscopy:

  • STORM/PALM: Achieve 10-20 nm resolution to precisely localize ESL-1 on microvilli and in the Golgi.

  • SIM: Provide 100 nm resolution with faster acquisition for live-cell imaging of ESL-1 dynamics.

  • STED: Enable detailed analysis of ESL-1 clustering and co-localization with binding partners.

• Intravital imaging:

  • Label hematopoietic cells with fluorescently conjugated anti-ESL-1 antibodies or use cells from ESL-1-fluorescent protein fusion knock-in mice.

  • Employ multiphoton or confocal intravital microscopy to visualize ESL-1-dependent cell migration in the bone marrow or at sites of inflammation.

  • Track individual cell behaviors in real-time to assess ESL-1's role in rolling, adhesion, and extravasation.

• Correlative light and electron microscopy (CLEM):

  • Use gold-conjugated anti-ESL-1 antibodies for immunogold labeling.

  • Combine with transmission electron microscopy to visualize ESL-1 at ultrastructural resolution.

  • Previous studies using immunogold scanning electron microscopy have already demonstrated ESL-1 localization on microvilli, but CLEM would provide additional contextual information .

• Proximity labeling techniques:

  • Generate ESL-1 fusions with APEX2 or BioID to identify proximal proteins in living cells.

  • Use antibodies against ESL-1 and candidate interacting proteins to validate proximity labeling results.

  • This approach could reveal new ESL-1 binding partners in different cellular compartments.

These advanced imaging approaches can provide unprecedented insights into ESL-1 localization, dynamics, and protein-protein interactions in diverse biological contexts .

How do anti-ESL-1 antibodies perform across different species models?

ESL-1 is evolutionarily conserved, with homologs identified in various species. When working with ESL-1 antibodies across species models, researchers should consider the following comparative aspects:

• Cross-reactivity analysis:

  • Most commercially available anti-ESL-1 antibodies are generated against mouse or human ESL-1.

  • Cross-reactivity between species varies significantly between antibody clones.

  • Sequence alignment analysis reveals that mouse ESL-1 shows high homology to chicken cysteine-rich FGF receptor (CFR) and rat Golgi protein MG160, suggesting potential cross-reactivity with these species .

• Species-specific considerations:

  • Mouse models: Most extensively studied, with validated antibodies and genetic models available.

  • Human samples: Some antibodies cross-react between mouse and human ESL-1; validation in human cells is essential.

  • Rat models: May benefit from antibodies targeting conserved epitopes shared with mouse ESL-1.

  • Non-mammalian models: Limited antibody options; consider using antibodies against highly conserved domains.

• Epitope conservation assessment:

  • Analyze sequence homology in specific antibody epitope regions across species.

  • Test antibody binding to recombinant ESL-1 from different species.

  • Validate antibody specificity in each species using knockdown or knockout controls.

How can researchers integrate ESL-1 antibody-based techniques with genetic approaches for comprehensive analysis?

Combining antibody-based detection with genetic manipulation provides a powerful approach for comprehensive analysis of ESL-1 biology. The following integration strategies are recommended:

• Complementary validation approach:

  • Use ESL-1 antibodies to confirm protein expression changes in genetic models.

  • Employ Glg1^-/-^ mice or cells as negative controls for antibody specificity.

  • Generate conditional knockout models to study tissue-specific ESL-1 functions while using antibodies to confirm deletion efficiency .

• Rescue experiments:

  • Reintroduce wild-type or mutant ESL-1 into Glg1^-/-^ cells.

  • Use antibodies to verify expression levels and localization of reintroduced proteins.

  • Assess functional rescue through E-selectin binding, migration, or proliferation assays.

• Domain-specific analysis:

  • Generate truncation or point mutation constructs targeting specific ESL-1 domains.

  • Use domain-specific antibodies to analyze expression and localization of mutant proteins.

  • Correlate structural alterations with functional outcomes in binding and signaling assays.

• Temporal control strategies:

  • Combine inducible genetic systems (e.g., tetracycline-regulated expression) with antibody detection.

  • Monitor protein dynamics after genetic manipulation using time-course antibody staining.

  • Use photoactivatable or photoconvertible fluorescent protein fusions with ESL-1 for live imaging.

This integrated approach has been successfully employed to demonstrate that hematopoietic-specific deletion of ESL-1 is sufficient to recapitulate the hematopoietic phenotypes observed in global knockout mice, confirming a cell-intrinsic role for ESL-1 in hematopoietic stem cell regulation .

How does ESL-1 compare functionally to other E-selectin ligands and what methodological approaches can distinguish their roles?

ESL-1 functions alongside other E-selectin ligands, particularly PSGL-1 and CD44. Distinguishing their individual and cooperative roles requires specialized methodological approaches:

• Comparative binding analysis:

  • Binding kinetics: Use surface plasmon resonance with recombinant E-selectin and purified ligands to compare association/dissociation rates and binding affinities.

  • Competitive binding assays: Pre-block cells with antibodies against individual ligands before measuring E-selectin binding to quantify their relative contributions.

  • Genetic hierarchy analysis: Compare E-selectin binding in single, double, and triple knockout cells lacking various combinations of ESL-1, PSGL-1, and CD44 .

• Functional contribution assessment:

  • Cell-type specific analysis: Compare ligand expression and function across different hematopoietic cell types (progenitors vs. mature cells).

  • Context-dependent roles: Examine ligand utilization in homeostasis versus inflammation using appropriate in vivo models.

  • Signaling pathway comparison: Analyze whether different ligands activate distinct downstream pathways upon E-selectin engagement .

• Specialized methodological approaches:

  • Microfluidic assays: Measure rolling velocity and adhesion strength of cells on E-selectin substrates after blocking specific ligands.

  • Intravital microscopy: Visualize cell recruitment in vivo in mice deficient for individual or multiple E-selectin ligands.

  • Domain swapping experiments: Generate chimeric proteins containing domains from different ligands to identify functional regions.